About AqueSys
AqueSys is a Healthcare company based in Aliso Viejo (United States) founded in 2006, and was acquired by Allergan in September 2015. Implantable devices for glaucoma treatment are developed by AqueSys. AqueSys has raised $87.6 million across 4 funding rounds from investors including The Carlyle Group, Allergan and Accuitive Medical Ventures. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Glaukos, Ivantis and Myra Vision; 3 of its 3 listed competitors have raised funding.
Company details
AqueSys was founded in 2006 in Aliso Viejo, United States, as an ophthalmic company. Focus is placed on implantable devices to manage glaucoma. The XEN Gel Stent, a gelatin-based implant for intraocular pressure control, was developed and received CE Mark approval in Europe. Injection occurs via a preloaded device through a self-sealing incision. Acquisition by Allergan took place in 2015, with US approval pending at that time.
- Headquarters Aliso Viejo, United States
- Stage Acquired
- SectorsHealthcare
- Website aquesys.com
- Social LinkedIn
- Acquired by Allergan (Sep 2015)
- Total Equity Funding$87.6M (USD)
in 4 rounds
- Latest Funding Round$43.6M (USD), Series D
Jan 2014
- InvestorsThe Carlyle Group
& 5 more
- Acquired byAllergan
(Sep 2015)
Funding Insights of AqueSys
AqueSys has successfully raised a total of $87.6M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $43.6 million completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87.6M
- Total Rounds 4
- Last Round Series D β $43.6M
- First Round $9M
(Jul 2008)
- Investors Count 5
All 4 funding rounds of AqueSys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2014 | $43.6M | Series D | β | β | |
| May 2012 | $12M | Debt – Conventional | β | β | β |
| Jun 2010 | $35M | Series C | β | Longitude Capital, Rho Capital Partners | |
| Jul 2008 | $9M | Series B | β | β |
6 investors in total: 6 institutional.
Investors in AqueSys
AqueSys has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include The Carlyle Group, Allergan and Accuitive Medical Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage US healthcare investments are made by Accuitive Medical Ventures. | amvpartners.com | Duluth, United States | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Private equity investments are directed toward multiple sectors. | 1986 | carlyle.com | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States |
Investor details for AqueSys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AqueSys
4 dated milestones of AqueSys across 9 years, from founding to its latest funding, stage changes and deals.
- Founded AqueSys is founded.
- Funding First funding round of $9.0M.
- Funding Latest funding round, Series D, of $43.6M.
- Exit Acquired by Allergan.
Competitors of AqueSys
AqueSys has 3 listed competitors in our database, 3 of them funded. They include Glaukos, Ivantis and Myra Vision.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| glaukos.com | 2001 | Laguna Hills, United States | $117.57M | 907 | Developer of implants to treat glaucoma | |
| ivantisinc.com | 2007 | Irvine, United States | $166.23M | 132 | Implantable device to relieve intraocular pressure in open angle glaucoma | |
| myravision.com | 2019 | Campbell, United States | $42M | Nanotechnology-based devices for glaucoma treatment are developed. |
Detailed competitors of AqueSys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as AqueSys (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 24.69 B | 25,941 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aquesys
Complete news archive for AqueSys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AqueSys
AqueSys was founded in 2006 and raised its 1st funding round 2 years after it was founded.
AqueSys is headquartered in Aliso Viejo, United States. It is registered at Aliso Viejo, California, United States.
AqueSys is a funded company, having raised a total of $87.6M across 4 funding rounds to date. The company's 1st funding round was a Series B of $9M, raised on Jul 2008.
AqueSys was founded in 2006 in Aliso Viejo, United States, as an ophthalmic company. Focus is placed on implantable devices to manage glaucoma. The XEN Gel Stent, a gelatin-based implant for intraocular pressure control, was developed and received CE Mark approval in Europe. Injection occurs via a preloaded device through a self-sealing incision. Acquisition by Allergan took place in 2015, with US approval pending at that time.
AqueSys's top competitors include Glaukos, Myra Vision and Ivantis.
AqueSys has 6 investors. Key investors include The Carlyle Group, Allergan, Accuitive Medical Ventures, Longitude Capital, and SV Health Investors.
Yes. AqueSys was acquired by Allergan in September 2015.

